Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis

BACKGROUND: Infliximab is a monoclonal antibody that binds and neutralizes circulating tumor necrosis factor-alpha, a key inflammatory cytokine in the pathophysiology of sarcoidosis. Despite the paucity of randomized clinical trials, infliximab is often considered a therapeutic option for refractory...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakkat, Abdullah, Cox, Gerard, Khalidi, Nader, Larche, Maggie, Beattie, Karen, Renzoni, Elisabetta A., Morar, Nilesh, Kouranos, Vasilis, Kolb, Martin, Hambly, Nathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905837/
https://www.ncbi.nlm.nih.gov/pubmed/35264154
http://dx.doi.org/10.1186/s12931-022-01971-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905837/
https://www.ncbi.nlm.nih.gov/pubmed/35264154
http://dx.doi.org/10.1186/s12931-022-01971-5

Ejemplares similares